Navigation Links
Genome of Irish potato famine pathogen decoded
Date:9/11/2009

ns genome comprises alternating repeat-rich (and gene-poor) regions and gene-dense regions;
  • These gene-dense regions are shared among other Phytophthora species, preserved over millions of years of evolution, whereas the repeat-rich regions are undergoing relatively rapid changes;
  • The repeat-rich regions contain fewer genes compared to other genomic regions, yet those genes they do contain are enriched for those that play crucial roles in plant infection.

    Taken together, these findings suggest an unusual genomic strategy to support the rapid evolution of critical genes, known as "effector" genes. Effector genes can disrupt plants' normal physiology, enabling the pathogen to establish a foothold. However, some can also trigger plants' immune responses, making them prime targets for combating P. infestans infection.

    "We think this could be a tactic that enables P. infestans to rapidly adapt to host plants," said co-lead author Brian Haas, manager of genome annotation, outreach, bioinformatics, and analysis at the Broad Institute. "In contrast to the well-conserved regions where most genes are found, the repeat-rich regions change rapidly over time, acting as a kind of incubator to enable the rapid birth and death of genes that are key to plant infection. As a result, these critical genes may be gained and lost so rapidly that the hosts simply can't keep up."

    Importantly, the new P. infestans genome sequence enabled the researchers to identify many previously unknown effector genes, particularly those that belong to two key groups, known as RXLR genes and CRN genes. The research team identified more than 500 RXLR genes and nearly 200 CRN genes, significantly more than are found in the pathogen's relatives.

    These findings not only expand the catalog of known P. infestans genes, they also highlight a critical subset of genes undergoing rapid turnover. Further studies of these genes will f
    '/>"/>


  • Contact: Nicole Davis
    ndavis@broadinstitute.org
    617-714-7152
    Broad Institute of MIT and Harvard
    Source:Eurekalert

    Page: 1 2 3 4

    Related biology news :

    1. UC Riverside research on barley genome gets boost from $1 million USDA grant
    2. Genomes reveal bacterial lifestyles: Research
    3. Zoo volunteers help explain mysteries of the genome
    4. Largest ever Alzheimers genome study unveils dementia mysteries
    5. Counting duplicated genome segments now possible
    6. Faster, cheaper way to find disease genes in human genome passes initial test
    7. Genome duplication responsible for more plant species than previously thought
    8. After dinosaurs, mammals rise but their genomes get smaller
    9. Springer to collaborate with the Human Genome Organization
    10. New national genome center launched
    11. CSHL scientists harness logic of Sudoku math puzzle to vastly enhance genome-sequencing capability
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6